IN2015DN03145A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03145A
IN2015DN03145A IN3145DEN2015A IN2015DN03145A IN 2015DN03145 A IN2015DN03145 A IN 2015DN03145A IN 3145DEN2015 A IN3145DEN2015 A IN 3145DEN2015A IN 2015DN03145 A IN2015DN03145 A IN 2015DN03145A
Authority
IN
India
Prior art keywords
compound
formula
14the
glaucoma
atherosclerosis
Prior art date
Application number
Other languages
English (en)
Inventor
Baledi; Dhurwasulu
Uwe Grether
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2015DN03145A publication Critical patent/IN2015DN03145A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3145DEN2015 2012-12-07 2013-12-04 IN2015DN03145A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196024 2012-12-07
PCT/EP2013/075444 WO2014086807A1 (en) 2012-12-07 2013-12-04 Novel pyrazine derivatives as cb2 receptor agonists

Publications (1)

Publication Number Publication Date
IN2015DN03145A true IN2015DN03145A (enrdf_load_stackoverflow) 2015-10-02

Family

ID=47290805

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3145DEN2015 IN2015DN03145A (enrdf_load_stackoverflow) 2012-12-07 2013-12-04

Country Status (32)

Country Link
US (1) US9512141B2 (enrdf_load_stackoverflow)
EP (1) EP2928882B1 (enrdf_load_stackoverflow)
JP (1) JP6322646B2 (enrdf_load_stackoverflow)
KR (1) KR20150092156A (enrdf_load_stackoverflow)
CN (1) CN104837830B (enrdf_load_stackoverflow)
AR (1) AR093804A1 (enrdf_load_stackoverflow)
AU (1) AU2013354115B2 (enrdf_load_stackoverflow)
BR (1) BR112015009603A2 (enrdf_load_stackoverflow)
CA (1) CA2885418A1 (enrdf_load_stackoverflow)
CL (1) CL2015001318A1 (enrdf_load_stackoverflow)
CR (1) CR20150210A (enrdf_load_stackoverflow)
CY (1) CY1118808T1 (enrdf_load_stackoverflow)
DK (1) DK2928882T3 (enrdf_load_stackoverflow)
EA (1) EA025840B1 (enrdf_load_stackoverflow)
ES (1) ES2621958T3 (enrdf_load_stackoverflow)
HR (1) HRP20170572T1 (enrdf_load_stackoverflow)
HU (1) HUE030836T2 (enrdf_load_stackoverflow)
IL (1) IL237982A (enrdf_load_stackoverflow)
IN (1) IN2015DN03145A (enrdf_load_stackoverflow)
LT (1) LT2928882T (enrdf_load_stackoverflow)
MA (1) MA38217B1 (enrdf_load_stackoverflow)
MX (1) MX2015006036A (enrdf_load_stackoverflow)
PE (1) PE20151060A1 (enrdf_load_stackoverflow)
PH (1) PH12015501072B1 (enrdf_load_stackoverflow)
PL (1) PL2928882T3 (enrdf_load_stackoverflow)
PT (1) PT2928882T (enrdf_load_stackoverflow)
RS (1) RS55951B1 (enrdf_load_stackoverflow)
SG (1) SG11201504011UA (enrdf_load_stackoverflow)
SI (1) SI2928882T1 (enrdf_load_stackoverflow)
TW (1) TW201427960A (enrdf_load_stackoverflow)
UA (1) UA116894C2 (enrdf_load_stackoverflow)
WO (1) WO2014086807A1 (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629751T3 (es) 2013-03-07 2017-08-14 F. Hoffmann-La Roche Ag Derivados de pirazol novedosos
WO2014154612A1 (en) 2013-03-26 2014-10-02 F. Hoffmann-La Roche Ag Novel pyridine derivatives
CN105209466B (zh) 2013-05-02 2018-05-18 豪夫迈·罗氏有限公司 作为cb2受体激动剂的嘌呤衍生物
UA116801C2 (uk) 2013-05-02 2018-05-10 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
PT3483163T (pt) 2013-09-06 2021-08-24 Hoffmann La Roche Novos derivados de triazolo[4,5-d]pirimidina como antagonistas de receptor cb2
JP6654574B2 (ja) * 2014-04-04 2020-02-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cb2アゴニストとして有用なピリジン−2−アミド
HRP20200606T1 (hr) 2015-12-09 2020-07-10 F. Hoffmann - La Roche Ag Derivati fenila kao agonisti kanabinoidnog receptora 2
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
JP7478672B2 (ja) 2018-06-27 2024-05-07 エフ. ホフマン-ラ ロシュ アーゲー カンナビノイド受容体2の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
EP3814337B1 (en) 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
SG11202009103WA (en) 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
CA2664621A1 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives

Also Published As

Publication number Publication date
HRP20170572T1 (hr) 2017-06-16
CY1118808T1 (el) 2018-01-10
EA025840B1 (ru) 2017-02-28
SI2928882T1 (sl) 2017-05-31
ES2621958T3 (es) 2017-07-05
MX2015006036A (es) 2015-08-07
PE20151060A1 (es) 2015-07-25
KR20150092156A (ko) 2015-08-12
US20150299220A1 (en) 2015-10-22
DK2928882T3 (en) 2017-02-20
EP2928882A1 (en) 2015-10-14
CA2885418A1 (en) 2014-06-12
JP2016505557A (ja) 2016-02-25
WO2014086807A1 (en) 2014-06-12
JP6322646B2 (ja) 2018-05-09
MA38217B1 (fr) 2017-11-30
IL237982A (en) 2017-06-29
CR20150210A (es) 2015-05-29
PH12015501072A1 (en) 2015-08-03
PH12015501072B1 (en) 2015-08-03
MA38217A1 (fr) 2017-02-28
SG11201504011UA (en) 2015-07-30
UA116894C2 (uk) 2018-05-25
AU2013354115B2 (en) 2017-10-05
CN104837830B (zh) 2018-07-20
AR093804A1 (es) 2015-06-24
RS55951B1 (sr) 2017-09-29
AU2013354115A1 (en) 2015-04-09
HUE030836T2 (en) 2017-06-28
TW201427960A (zh) 2014-07-16
HK1208030A1 (en) 2016-02-19
EA201590827A1 (ru) 2015-09-30
EP2928882B1 (en) 2017-01-18
CL2015001318A1 (es) 2015-10-02
BR112015009603A2 (pt) 2017-07-04
US9512141B2 (en) 2016-12-06
LT2928882T (lt) 2017-03-27
PT2928882T (pt) 2017-03-16
CN104837830A (zh) 2015-08-12
PL2928882T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
IN2015DN03145A (enrdf_load_stackoverflow)
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
UA110338C2 (xx) Хімічні сполуки
PH12015501073A1 (en) Novel pyridine derivatives
PH12014501417A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PH12015500376B1 (en) Novel bicyclic pyridinones
MX2011008602A (es) Metodos de tratamiento de condiciones relacionadas con el cabello.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
PH12016501849A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2015014470A (es) Analogos de combretastatina.
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX2015000804A (es) Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
GB201119089D0 (en) Treatment of musculoskeletal fibroproliferative disorders
FI20116033A0 (fi) Uudet ei-steroidiset yhdisteet androgeenireseptorin muuntelijoina
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.